{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.7","upperLimit":"61.1","value":"53.5"},{"groupId":"OG001","lowerLimit":"0.4","upperLimit":"11.7","value":"3.4"},{"groupId":"OG002","lowerLimit":"0.2","upperLimit":"33.9","value":"7.1"},{"groupId":"OG003","lowerLimit":"0.4","upperLimit":"57.9","value":"14.3"},{"groupId":"OG004","lowerLimit":"18.0","upperLimit":"57.5","value":"36.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"25"}],"units":"Participants"}],"description":"A secondary endpoint is confirmed PSA (prostate-specific antigen) response (≥ 50% reduction) as assessed by local laboratory. Confirmed PSA response is analyzed for all patients who had PSA value at baseline and is defined as the percentage of patients having 2 consecutive PSA values (at least 3 weeks apart) that are at least 50% lower than baseline and that occur prior to PSA progression. PSA progression is defined as a ≥ 25% increase and absolute increase of ≥ 2 ng/mL above the nadir in PSA.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a deleterious BRCA (breast cancer susceptibility gene) mutation detected in their tumor.","id":"OG000","title":"BRCA Mutation"},{"description":"Patients with a deleterious ATM (ataxia telangiectasia mutated serine/threonine kinase) mutation detected in their tumor.","id":"OG001","title":"ATM Mutation"},{"description":"Patients with a deleterious CDK12 (Cyclin-dependent kinase 12) mutation detected in their tumor.","id":"OG002","title":"CDK12 Mutation"},{"description":"Patients with a deleterious CHEK2 (Checkpoint Kinase 2) mutation detected in their tumor.","id":"OG003","title":"CHEK2 Mutation"},{"description":"Patients with other deleterious HRR (homologous recombination repair) gene mutation detected in their tumor.","id":"OG004","title":"Other Gene Mutation"}],"paramType":"NUMBER","populationDescription":"All patients who had a PSA value at baseline.","reportingStatus":"POSTED","timeFrame":"PSA assessments were done at baseline, Week 5, Week 9, every 4 weeks thereafter, and at Treatment Discontinuation. Total follow-up was up to approximately 39 months.","title":"Confirmed PSA Response (≥ 50% Decrease) by Gene as Assessed by Local Laboratory","type":"SECONDARY","unitOfMeasure":"percentage of participants"}